Yıl: 2020 Cilt: 42 Sayı: 3 Sayfa Aralığı: 242 - 247 Metin Dili: İngilizce DOI: 10.14744/etd.2020.99836 İndeks Tarihi: 18-06-2021

Coronavirus Disease 2019 (COVID-19): Diagnosis and Management

Öz:
The coronavirus family has significant human and animal pathogens. At the end of December 2019, a novel coronaviruswas recognized as the reason for a group of pneumonia cases of unidentified etiology in Wuhan, a city in the Hubei Provinceof China. The novel coronavirus has rapidly become widespread, resulting in an epidemic throughout China, followed by apandemia, an increasing number of cases in various countries throughout the world. Coronavirus disease 2019 (COVID-19)is spread through large droplets produced during coughing and sneezing by symptomatic patients, as well as asymptomaticindividuals before starting of their symptoms. The incubation period of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection is assumed to be 14 days succeeding exposure, mostly around four to five days. Individuals of all agesmay acquire SARS-CoV-2 infection, although middle age and older individuals are the majority. The usual clinical characteristicsinvolve fever, dry cough, fatigue, sore throat, rhinorrhea, conjunctivitis headache, myalgia, dyspnea, nausea, vomitingand diarrhea. Hence, there are no unique clinical features that yet dependably differentiate COVID-19 disease from otherupper/lower airway viral infections. In a subgroup of cases, by the end of the first week, COVID-19 disease may developto pneumonia, pulmonary failure and death. The aim is here to discuss the COVID-19 disease beginning from virology,epidemiology and continuing with clinical manifestations, diagnosis, its complications and to finish with available therapeuticoptions and conclusion.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. National Health Commission of the People’s Republic of China. New coronavirus cases rise to 571 in Chinese mainland. Available from: URL: http://en.nhc.gov.cn/2020-01/23/c_76004.htm. Accessed, January 23, 2020.
  • 2. European Centre for Disease Prevention and Control. Geographical distribution of 2019-nCov cases. Available from: URL: https://www. ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Accessed, January 26, 2020.
  • 3. World Health Organization. Novel coronavirus situation report -2. January 22, 2020. Available from: URL: https://www.who.int/docs/ default-source/coronaviruse/situation-reports/20200122-sitrep-2- 2019-ncov.pdf. Accessed, January 23, 2020.
  • 4. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Availabl from: URL: https:// www.who.int/dg/speeches/detail/who-director-general-s-remarks -at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed, February 12, 2020.
  • 5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–33.
  • 6. Xinhua. China’s CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan. Available from: URL: https://www.xinhuanet.com/2020-01/27/c_1125504355.htm. Accessed, February 20, 2020.
  • 7. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. Available from: URL: https://www.biorxiv.org/content/10.1101/ 2020.02.07.937862v1.full.pdf+html. Accessed February 12, 2020.
  • 8. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270–3.
  • 9. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020; 382(10): 970–1.
  • 10. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020; 104(3): 246–51.
  • 11. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-2019). February 16-24, 2020. http://www.who.int/docs/default- source/coronaviruse/who-china-joint-mission-on-covid-19-finalreport. pdf. Accessed, March 4, 2020.
  • 12. Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M, et al. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020. MMWR Morb Mortal Wkly Rep 2020; 69(9): 245–6.
  • 13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032. [Epub ahead of print].
  • 14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–13
  • 15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–9.
  • 16. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 24 February 2020. Available from: URL: https://www.who.int/dg/speeches/detail/who-director-general-s-opening- remarks-at-themedia-briefing-on-covid-19---24-february-2020. Accessed, February 26, 2020.
  • 17. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 Mar 4. doi:10.1007/s11427-020-1661-4. [Epub ahead of print].
  • 18. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239–42.
  • 19. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13. doi:10.1001/jamainternmed.2020.0994. Epub ahead of print].
  • 20. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020 Apr 2. doi: 10.1007/s11684-020- 0767-8. [Epub ahead of print].
  • 21. Coronavirus Outbreak. Available from: URL: https://www.worldometers. info/coronavirus/. Accessed, 23 Feb 2020.
  • 22. Report of the WHO-China Joint Mission on Coronavirus DIsease 2019 (COVID-2019). February 16-24, 2020. Available from: URL: http:// www.who.int/docs/default-source/coronaviruse/who-china-joint-mission- on-covid-19- final-report.pdf. Accessed, March 04, 2020.
  • 23. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA. 2020 Mar 13. doi: 10.1001/jama.2020.4031. [Epub ahead of print].
  • 24. KCDC. Updates on COVID-19 in Korea. March 14, 2020. Available from: URL: https://www.cdc.go.kr/board/board.es?mid=a30402000000 &bid=0030. Accessed, March 14, 2020.
  • 25. Zu F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054–62.
  • 26. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr. 2020 Feb 7. doi: 10.1007/s12519-020-00343-7. [Epub ahead of print]
  • 27. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven Faces of Coronavirus Disease 2019. Allergy. 2020 Mar 20. doi: 10.1111/ all.14289. [Epub ahead of print]
  • 28. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281–6.
  • 29. Wang C, Liu Z, Chen Z, Huang X, Xu M, He T, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020 Mar 13. doi: 10.1002/jmv.25762. [Epub ahead of print]
  • 30. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARSCoV- 2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020; 382(12): 1177–9.
  • 31. Interim guidelines for collecting, handling, and testing clinical specimens from persons under investigation (PUIs) for coronavirus disease 2019 (COVID-19). Available from: URL: https:// www.cdc.gov/ coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html. Accessed, March 15, 2020.
  • 32. Tang YW, Schmitz JE, Persing DH, Stratton CW. The Laboratory Diagnosis of COVID 19 infection: Current issues and challenges. J Clin Microbiol. 2020 Apr 3. pii: JCM.00512-20. doi: 10.1128/ JCM.00512-20. [Epub ahead of print]
  • 33. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506.
  • 34. Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020 Mar 10:200823. doi: 10.1148/ radiol.2020200823. [Epub ahead of print]
  • 35. Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology 2020; 295(1): 22–3.
  • 36. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol 2020; 30(3): 313–24.
  • 37. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 Mar 27. doi: 10.1001/jama.2020.4783. [Epub ahead of print]
  • 38. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with Lopinavir/Ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212(12): 1904–13.
  • 39. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci 2020; 35(6): e79.
  • 40. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020; 7(1): 11.
  • 41. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269–71.
  • 42. Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020 Apr 2:101647. doi: 10.1016/j. tmaid.2020.101647. [Epub ahead of print]
  • 43. Ji XG, Zhao YH, Zhang M, Zhao JH, Wang JY, et al. The experimental study of the anti-SARS-CoV effect of Arbidole. Pharm J Chin PLA 2004; 20: 274–6.
  • 44. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi: 10.1093/ cid/ciaa237. [Epub ahead of print]
  • 45. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020; 21(7). pii: E2272. doi: 10.3390/ijms21072272. [Epub ahead of print]
  • 46. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020; 9(1): 382–5.
  • 47. Wang BX, Fish EN. Global virus outbreaks: interferons as 1st responders. Semin Immunol 2019; 43: 101300.
  • 48. Conti P, Gallenga CE, Tetè G, Caraffa A, Ronconi G, Younes A, et al. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARSCoV- 2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents. 2020 Mar 31;34(2). doi: 10.23812/Editorial- Conti-2. [Epub ahead of print]
  • 49. Reuters. China approves use of Roche drug in battle against coronavirus complications. Available from: URL: https:// www.reuters. com/article/us-health-coronavirus-china-roche-hldg/china-approvesuse- of-rochearthritis-drug-for-coronavirus-patients-idUSKBN20R0LF. Accessed, March 11, 2020.
  • 50. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDAapproved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020 Apr 3:104787. doi: 10.1016/j.antiviral. 2020.104787. [Epub ahead of print]
  • 51. World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance: Patient management. Available from: URL: https://www. who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/ patient-management. Accessed, February 02, 2020.
  • 52. Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: E007.
  • 53. Ulu Kilic A, Kara F, Alp E, Doganay M. New threat: 2019 novel Coronavirus infection and infection control perspective in Turkey. North Clin Istanb 2020; 7(2): 95–8.
APA Özdemir Ö (2020). Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. , 242 - 247. 10.14744/etd.2020.99836
Chicago Özdemir Öner Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. (2020): 242 - 247. 10.14744/etd.2020.99836
MLA Özdemir Öner Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. , 2020, ss.242 - 247. 10.14744/etd.2020.99836
AMA Özdemir Ö Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. . 2020; 242 - 247. 10.14744/etd.2020.99836
Vancouver Özdemir Ö Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. . 2020; 242 - 247. 10.14744/etd.2020.99836
IEEE Özdemir Ö "Coronavirus Disease 2019 (COVID-19): Diagnosis and Management." , ss.242 - 247, 2020. 10.14744/etd.2020.99836
ISNAD Özdemir, Öner. "Coronavirus Disease 2019 (COVID-19): Diagnosis and Management". (2020), 242-247. https://doi.org/10.14744/etd.2020.99836
APA Özdemir Ö (2020). Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. Erciyes Medical Journal, 42(3), 242 - 247. 10.14744/etd.2020.99836
Chicago Özdemir Öner Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. Erciyes Medical Journal 42, no.3 (2020): 242 - 247. 10.14744/etd.2020.99836
MLA Özdemir Öner Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. Erciyes Medical Journal, vol.42, no.3, 2020, ss.242 - 247. 10.14744/etd.2020.99836
AMA Özdemir Ö Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. Erciyes Medical Journal. 2020; 42(3): 242 - 247. 10.14744/etd.2020.99836
Vancouver Özdemir Ö Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. Erciyes Medical Journal. 2020; 42(3): 242 - 247. 10.14744/etd.2020.99836
IEEE Özdemir Ö "Coronavirus Disease 2019 (COVID-19): Diagnosis and Management." Erciyes Medical Journal, 42, ss.242 - 247, 2020. 10.14744/etd.2020.99836
ISNAD Özdemir, Öner. "Coronavirus Disease 2019 (COVID-19): Diagnosis and Management". Erciyes Medical Journal 42/3 (2020), 242-247. https://doi.org/10.14744/etd.2020.99836